Well said stockrock. To be fair, I don't think there was any...

Well said stockrock.

To be fair, I don't think there was any certainty at the point of merger. RWL and MABR were still nascent in their businesses despite their claim to 7,000 references worldwide. For Emefcy, all they had were a lot of inquiries for pilot plants, a set of wrong SOEs for partners, and a production plant in China.

Now that they have sold > 250 plants worldwide, it is about time to pivot, shed off the nice-to-have's and focus on the must-have. To not pivot, stay to the same old, same old, and expect things to improve is bordering on insanity.

With 100% hindsight, it was insanity to invest in FLC in 2018 on nothing but promises. But now, it is different. Aspiral's suite of products are proven. They are guiding USD$35m to $50m from SPS. When the pandemic is lifted and travel is restored, the pace of closing deals will accelerate because MABR is becoming a great-to-have when Decentralised Wastewater Treatment Systems (DEWATS) is becoming a must have. https://sswm.info/sites/default/files/reference_attachments/DEWATS_Guidebook_small.pdf.